.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,132,420

« Back to Dashboard
Patent 6,132,420 protects VIADUR and is included in one NDA.

This patent has seventy-seven patent family members in twenty-nine countries.

Summary for Patent: 6,132,420

Title: Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
Abstract:The present invention relates to an osmotically driven agent delivery system for delivering a beneficial agent. The osmotic delivery system includes an osmotic agent which operates by imbibing fluid from an outside environment, causing the release of a beneficial agent. The osmotic delivery system includes a liquid or gel additive surrounding the osmotic agent for enhancing start-up and lubricating the osmotic agent. The liquid or gel additive is an incompressible lubricating fluid which fills any air gaps between the osmotic agent and the walls of a chamber and substantially reduces start-up delays.
Inventor(s): Dionne; Keith E. (Cambridge, MA), Lautenbach; Scott D. (San Mateo, CA)
Assignee: Alza Corporation (Mountain View, CA)
Application Number:08/970,530
Patent Claim Types:
see list of patent claims
Delivery; Device; Dosage form; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 24th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ortho Mcneil Janssen
VIADUR
leuprolide acetate
IMPLANT;IMPLANTATION021088-001Mar 3, 2000DISCNNo6,132,420► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,132,420

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,535,701Sustained delivery of an active agent using an implantable system► subscribe
6,635,268 Sustained delivery of an active agent using an implantable system► subscribe
5,728,396 Sustained delivery of leuprolide using an implantable system► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,132,420

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina006079► subscribe
Argentina010595► subscribe
Austria235224► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc